No abstract

Aims: This study aims to identify differences in parental satisfaction between three distinct types of intensive insulin therapies used for children with type 1 diabetes (T1D) namely multiple daily injection (MDI), continuous subcutaneous insulin infusion (CSII) and flexible multiple daily injection (fMDI). Materials and Methods: Data was collected over a 6-month period during the quarterly clinic visits. Two modified versions of validated tools-Insulin Treatment Satisfaction Questionnaire (ITSQ) and Diabetes Treatment Satisfaction Questionnaire (DTSQ), were electronically filled in by the parents of children with T1D. This provided information on parental satisfaction on the following areas: inconvenience of regimen, lifestyle flexibility, impression of glycaemic control, fear of hypoglycaemia, diabetic symptoms, treatment barriers, worry, treatment adherence and communication. Results: 34 parents completed the electronic data forms on iSurvey. Parents of the fMDI group were the most confident to avoid severe hypoglycaemia whereas MDI-parents being the least confident, t (21) = 2.12, p = 0.046. There was no statistical difference noted on how confident parents felt to avoid asymptomatic hypoglycaemia, their worry about nocturnal hypoglycaemia, convenience and ease of using insulin in public places, nor was there statistically significant difference in the pain and discomfort felt by their children. Parents of children with fMDI felt the time their children spent with hyperglycemia was higher than the MDI, t (21) = 2.11, p = 0.047. Parents of the CSII group were most likely to continue their current treatment and were also, most likely to recommend the treatment regimen to others. Parents of MDI were least likely to do so, t (20) = 2.12, p =.047 and t (18) = 2.35, p = 0.031. Conclusion: Although this study was conducted with a very small sample size, it has revealed no significant difference in parental satisfaction among MDI, CSII and fMDI groups including parental anxiety and stress, ease of use in public places, convenience, flexibility, parental perception of pain and discomfort experienced by their children and fear of nocturnal hypoglycaemia. However, parents indicated greater confidence in avoiding severe hypoglycaemia in fMDI albeit there was higher glycaemic variability. Parents with CSII were more satisfied with treatment and more likely to recommend their current treatment option to others, than fMDI and MDI, as the preferred mode of treatment.

No abstract

Aims: This study aims to identify differences in diabetes specific health related quality of life (HRQoL) in children and adolescents with type 1 diabetes mellitus (T1D) treated with three distinct types of intensive insulin therapymultiple daily injection (MDI), continuous subcutaneous insulin infusion (CSII) and flexible multiple daily injection (fMDI). Materials and Methods: This survey was conducted in north west Tasmania over a 6-month period, during quarterly clinic visits. A well-known, reliable and validated survey tool -Paediatric Quality of life (PedsQL) Diabetes Module 3.0 was used to capture information about the diabetic specific HRQoL in children and adolescents. The parent-proxy version of the forms was completed by the parents electronically using iSurvey application to secure information regarding their children's diabetes related symptoms (11 items), treatment barriers (4 items), treatment adherence (7 items), worry (3 items) and communication (3 items). All de-identified information was downloaded into an excel spreadsheet and SPSS V24.0 for further analysis. Results: 34 parents completed the electronic data forms on iSurvey. There were no statistically significant differences in HRQoL among the CSII, MDI and fMDI groups as determined by one-way ANOVA in diabetes {F (2, 31) = 0.517, p = 0.601}, treatment {F (2, 31) = 0.385, p = 0.684}, worry {F (2, 31) = 0.076, p = 0.927}, and communication {F (2, 31) = 0.672, p = 0.518}. Conclusion: Although, the impact of T1D on the HRQoL in children and adolescents is higher than the children without T1D, it appears to be independent of the types of three intensive insulin therapy generally used-CSII, MDI and fMDI, suggesting type of insulin therapy may not be the major influencing factor for children' quality of life as revealed in this first of its kind study. A further study with higher number of participants and the additional impact of various glucose monitoring systems on the HRQoL is highly recommended, which may influence the decision of right therapy suitable for the entire family.

No abstract